

Filed January 20, 2026

On behalf of **Dr. Falk Pharma GmbH**

By: Nathanael R. Luman (Reg. No. 63,160)
Eric S. Furman (Reg. No. 45,664)
Jared C. Bunker (Reg. No. 58,474)
Phillip J. Minnick (Reg. No. 81,223)
KNOBBE, MARTENS, OLSON & BEAR, LLP
3579 Valley Centre Drive, Suite 300
San Diego, CA 92130
Ph: 949-760-0404
Email: BoxFalkPharma@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. FALK PHARMA GMBH,
Petitioner,

v.

ELLODI PHARMACEUTICALS, L.P.,
Patent Owner.

Case IPR2025-00054
Patent No. 11,246,828

PETITIONER'S REQUEST FOR ORAL ARGUMENT

Under the Scheduling Order (Paper 9), the due date for requesting Oral Argument in this proceeding is January 20, which cannot be extended. Patent Owner recently filed a statutory disclaimer disclaiming all claims from the patent that is the subject of this IPR. EX3002. In view of Patent Owner's disclaimer, the Board has authorized Patent Owner to file a motion to terminate this proceeding that includes a request for adverse judgment against Patent Owner. Paper 30. Patent Owner's motion to terminate has not yet been filed.

Petitioner Dr. Falk Pharma GmbH ("Petitioner") seeks to preserve its right to Oral Argument in this proceeding should Patent Owner's forthcoming motion to terminate and request for adverse judgment not be granted. Therefore, pursuant to 37 C.F.R. § 42.70(a), Petitioner respectfully requests an in-person oral argument in this proceeding, which is currently scheduled for March 2, 2026.

Petitioner is concurrently filing a request for oral argument in the related proceedings of IPR2025-00052 regarding U.S. 10,632,069; IPR2025-00055 regarding U.S. 9,486,407; and IPR2025-00056 regarding U.S. 11,260,061. The oral argument for each of these related proceedings also is scheduled for March 2, 2026.

Petitioner respectfully requests that each party be allotted 60 minutes of argument per side, in which all four related proceedings shall be jointly argued. Petitioner requests that the joint hearing be conducted at the USPTO headquarters in Alexandria, Virginia. Petitioner has conferred with Patent Owner via email. Patent

Owner does not object to Petitioner's request of 60 minutes per side and for the joint hearing to be held in Alexandria, Virginia.

Without waiving consideration of any issue not listed below, the issues to be argued include:

1. The unpatentability of each challenged claim from U.S. Patent No. 11,246,828 over all grounds asserted in the Petition for IPR2025-00054, including all issues raised in the parties' briefings and evidence submitted in connection with the asserted grounds;
2. Any issues raised by Patent Owner in its request for oral argument or otherwise presented by the Patent Owner;
3. Any other relevant issue raised in papers filed in this proceeding, including issues raised in papers yet to be filed; and,
4. Any additional issues on which the Board seeks clarification.

Petitioner requests the ability to use video equipment to display demonstrative exhibits, including a computer, projector and screen for a PowerPoint display.

Respectfully submitted,

Dated: January 20, 2026

By: /Nathanael R. Luman/

Nathanael R. Luman (Reg. No. 63,160)
KNOBBE MARTENS OLSON & BEAR, LLP

Attorney for Petitioner Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P.
IPR2025-00054

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on the date below a copy of this
PETITIONER’S REQUEST FOR ORAL ARGUMENT was served by email to
counsel for Ellodi at addresses below:

Sanya Sukduang
ssukduang@cooley.com

Jonathan Davies
jdavies@cooley.com

Jonathan Cousin
jcousin@cooley.com

Isha Agarwal
iagarwal@cooley.com

Ellodi_IPR@cooley.com

Dated: January 20, 2026

By: /Nathanael R. Luman/

Nathanael R. Luman (Reg. No. 63,160)
KNOBBE MARTENS OLSON & BEAR, LLP